海特生物拟在境外发行H股并在香港联交所上市

Core Viewpoint - Hite Bio (300683.SZ) plans to initiate the process for issuing H-shares and listing on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [2][3]. Company Overview - Hite Bio is a high-tech biopharmaceutical company aiming to become a leading Chinese innovative drug enterprise, listed on the Shenzhen Stock Exchange since August 8, 2017 [3]. - The company specializes in the production and sales of biological engineering products and lyophilized powder injections, with 25 production licenses for biological and chemical drugs [3]. - Hite Bio focuses on the research and production of drugs for the nervous system and oncology, having launched a class I biological new drug—injectable nerve growth factor NGF, and a class I genetically engineered biological new drug—injectable Epinastine [3].